{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:06:19Z","timestamp":1789711579775,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AbbVie GK"},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40123-022-00493-z","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T15:05:36Z","timestamp":1647702336000},"page":"1147-1161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02916017","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5016-851X","authenticated-orcid":false,"given":"Kenichi","family":"Namba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Kaburaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Tsuruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"issue":"2","key":"493_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10384-020-00809-1","volume":"65","author":"KH Sonoda","year":"2021","unstructured":"Sonoda KH, Hasegawa E, Namba K, et al. Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65(2):184\u201390.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"493_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/eye.2011.255","volume":"26","author":"RW Lee","year":"2012","unstructured":"Lee RW, Dick AD. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond). 2012;26(1):17\u201328.","journal-title":"Eye (Lond)"},{"key":"493_CR3","first-page":"w20025","volume":"149","author":"DC Rossi","year":"2019","unstructured":"Rossi DC, Ribi C, Guex-Crosier Y. Treatment of chronic non-infectious uveitis and scleritis. Swiss Med Wkly. 2019;149:w20025.","journal-title":"Swiss Med Wkly"},{"issue":"1\u20132","key":"493_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40123-014-0023-x","volume":"3","author":"C Castiblanco","year":"2014","unstructured":"Castiblanco C, Foster CS. Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol Ther. 2014;3(1\u20132):17\u201336.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"493_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492\u2013513.","journal-title":"Am J Ophthalmol"},{"key":"493_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3389\/fphar.2020.00655","volume":"11","author":"RA Valenzuela","year":"2020","unstructured":"Valenzuela RA, Flores I, Urrutia B, et al. New pharmacological strategies for the treatment of non-infectious uveitis. A minireview. Front Pharmacol. 2020;11:655.","journal-title":"Front Pharmacol"},{"issue":"1","key":"493_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","volume":"21","author":"S Ohno","year":"2019","unstructured":"Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21(1):2.","journal-title":"Arthritis Res Ther"},{"key":"493_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5772\/intechopen.82800","volume-title":"Advances in the diagnosis and management of uveitis","author":"JL Chen","year":"2019","unstructured":"Chen JL, Lobo-Chan A-M, Chan RVP, Bhat P. Tumor necrosis factor-alpha inhibitory therapy for non-infectious autoimmune uveitis. In: Rodriguez-Garcia A, Foster CS, editors. Advances in the diagnosis and management of uveitis. London: IntechOpen; 2019. p. 115\u201333. https:\/\/doi.org\/10.5772\/intechopen.82800."},{"issue":"10","key":"493_CR9","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932\u201343.","journal-title":"N Engl J Med"},{"issue":"10050","key":"493_CR10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183\u201392.","journal-title":"Lancet"},{"key":"493_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3899\/jrheum.140102","volume":"91","author":"F Cantini","year":"2014","unstructured":"Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47\u201355.","journal-title":"J Rheumatol Suppl"},{"issue":"sup1","key":"493_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(sup1):11\u201334.","journal-title":"Expert Opin Drug Saf"},{"key":"493_CR13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","volume":"128","author":"EB Suhler","year":"2021","unstructured":"Suhler EB, Jaffe GJ, Fortin E, et al. Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2021;128:899\u2013909.","journal-title":"Ophthalmology"},{"key":"493_CR14","doi-asserted-by":"publisher","first-page":"1623847","DOI":"10.1155\/2019\/1623847","volume":"2019","author":"A Bitossi","year":"2019","unstructured":"Bitossi A, Bettiol A, Silvestri E, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediat Inflamm. 2019;2019:1623847.","journal-title":"Mediat Inflamm"},{"issue":"5","key":"493_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","volume":"102","author":"C Fabiani","year":"2018","unstructured":"Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Beh\u00e7et\u2019s disease-related uveitis: a 4-year follow-up study. Br J Ophthalmol. 2018;102(5):637\u201341.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"493_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10067-018-4228-6","volume":"38","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38(2):407\u201315.","journal-title":"Clin Rheumatol"},{"key":"493_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1857791","author":"T Hiyama","year":"2021","unstructured":"Hiyama T, Harada Y, Kiuchi Y. Efficacy and safety of adalimumab therapy for the treatment of non-infectious uveitis: efficacy comparison among uveitis aetiologies. Ocul Immunol Inflamm. 2021. https:\/\/doi.org\/10.1080\/09273948.2020.1857791.","journal-title":"Ocul Immunol Inflamm"},{"key":"493_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1791346","author":"K Kunimi","year":"2020","unstructured":"Kunimi K, Usui Y, Asakage M, et al. Anti-TNF-\u03b1 therapy for refractory uveitis associated with Beh\u00e7et\u2019s syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm. 2020. https:\/\/doi.org\/10.1080\/09273948.2020.1791346.","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"493_CR19","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1136\/bjophthalmol-2017-311234","volume":"102","author":"JT Lee","year":"2018","unstructured":"Lee JT, Yates WB, Rogers S, Wakefield D, McCluskey P, Lim LL. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol. 2018;102(12):1672\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"493_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/APO.0000000000000380","volume":"10","author":"J Sota","year":"2021","unstructured":"Sota J, Gentileschi S, Vitale A, et al. Effectiveness of SB5, an adalimumab biosimilar, in patients with noninfectious uveitis: a real-life monocentric experience. Asia Pac J Ophthalmol (Phila). 2021;10(4):360\u20135.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"1","key":"493_CR21","doi-asserted-by":"publisher","first-page":"e000819","DOI":"10.1136\/bmjophth-2021-000819","volume":"6","author":"TL Tang-Lee-Say","year":"2021","unstructured":"Tang-Lee-Say TL, Yang V, Fingret JM, et al. Adalimumab in patients with vision-threatening uveitis: real-world clinical experience. BMJ Open Ophthalmol. 2021;6(1):e000819.","journal-title":"BMJ Open Ophthalmol."},{"key":"493_CR22","unstructured":"World Health Organization. Global Tuberculosis Report. 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/336069\/9789240013131-eng.pdf. Accessed 8 Jul 2021."},{"key":"493_CR23","unstructured":"Japanese Ocular Inflammation Society. TNF Inhibitor Use Guidelines and Safety Measures Manual for Non-Infectious Uveitis (2nd Edition) [in Japanese]. 2019. http:\/\/jois.umin.jp\/TNF.pdf. Accessed 8 Jul 2021."},{"issue":"3","key":"493_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"493_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","volume":"92","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467\u201371.","journal-title":"Ophthalmology"},{"issue":"3","key":"493_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3414\/ME12-01-0063","volume":"52","author":"B Trusko","year":"2013","unstructured":"Trusko B, Thorne J, Jabs D, et al. The Standardization of Uveitis Nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52(3):259\u201365.","journal-title":"Methods Inf Med"},{"issue":"7","key":"493_CR27","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"493_CR28","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1167\/iovs.08-3225","volume":"50","author":"IJ Su\u00f1er","year":"2009","unstructured":"Su\u00f1er IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50(8):3629\u201335.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"493_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/09273948.2018.1491605","volume":"27","author":"H Goto","year":"2019","unstructured":"Goto H, Zako M, Namba K, et al. Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflamm. 2019;27(1):40\u201350.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"493_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis. 2013;72(4):517\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"493_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3109\/14397595.2013.843760","volume":"24","author":"T Koike","year":"2014","unstructured":"Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24(3):390\u20138.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"493_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3109\/s10165-011-0541-5","volume":"22","author":"T Koike","year":"2012","unstructured":"Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3000 patients. Mod Rheumatol. 2012;22(4):498\u2013508.","journal-title":"Mod Rheumatol"},{"issue":"9","key":"493_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/ecco-jcc\/jjw060","volume":"10","author":"H Ogata","year":"2016","unstructured":"Ogata H, Watanabe M, Matsui T, et al. Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn\u2019s disease. J Crohns Colitis. 2016;10(9):1033\u201341.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"493_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5217\/ir.2020.00013","volume":"19","author":"Y Suzuki","year":"2021","unstructured":"Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T. Is adalimumab safe and effective in patients with intestinal Behcet\u2019s disease in real-world practice? Intest Res. 2021;19(3):301\u201312.","journal-title":"Intest Res"},{"issue":"2","key":"493_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard.2007.072967","volume":"67","author":"T Takeuchi","year":"2008","unstructured":"Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"493_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/2013.jamaophthalmol.102","volume":"131","author":"RK Naik","year":"2013","unstructured":"Naik RK, Rentz AM, Foster CS, et al. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol. 2013;131(2):219\u201325.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"493_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jamaophthalmol.2017.0603","volume":"135","author":"J Sheppard","year":"2017","unstructured":"Sheppard J, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135(6):511\u20138.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"493_CR38","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"493_CR39","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","volume":"103","author":"SC Manson","year":"2009","unstructured":"Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103(7):975\u201394.","journal-title":"Respir Med"},{"issue":"6","key":"493_CR40","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JWJ, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952\u20137.","journal-title":"Ann Rheum Dis"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-022-00493-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T17:54:56Z","timestamp":1652810096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-022-00493-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["493"],"URL":"https:\/\/doi.org\/10.1007\/s40123-022-00493-z","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}